Phase I study of Docetaxel, Cisplatin and S-1 in patients with advanced or recurrent gastric cancer

Phase I study of Docetaxel, Cisplatin and S-1 in patients with advanced or recurrent gastric cancer - Phase I study of DCS therapy for advanced gastric cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000978

Enrollment

Registered

2008-01-09

Start date

2007-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Docetaxel 20-40mg/m2 Cisplatin 60mg/m2 S-1 80mg/m2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. histologically proven adenocarcinoma of unresectable or recurrent gastric cancer 2. Age 20-75 3. PS 0-1 4. Patients with assessable lesion 5. No previous chemotherapy, or never proven of refractory to S-1 6. No history of chemotherapy for other than gastric cancer 7. Adequate bone marrow function 8. Life expectancy > 8weeks 9. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Active infection 2. Severe peritoneal metastasis 3. Massive pleural effusion 4. CNS metastasis 5. Severe diarrhea 6. Suspected of Interstitial Pneumonitis 7. Other severe complications 8. Active malignancy 9. Pregnant

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactShuichi Hironaka

Shizuoka Cancer Center Division of Gastrointestinal Oncology

s.hironaka@scchr.jp055-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026